A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Treatment options for prostate cancer have dramatically expanded. Facing a prostate cancer diagnosis often raises concerns among men and their partners: will treatment affect intimacy and their ...

Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. To confirm the diagnosis, biopsies are required. A team of researchers has now ...

Prostate health remains a crucial topic that many men avoid discussing, even with close family members. Early screenings can make a significant difference in detecting issues before they become severe ...

One of the most common concerns about treating prostate cancer is preserving sexual function and urinary control. For some prostate cancers, newer treatments offering an alternative to radiation and ...

The understanding of prostate cancer has significantly evolved in the past 15 years. However, many people—including primary care providers—may not be aware of the current guidelines for prostate ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...